- Type / Class
- Equity / Common Stock
- Shares outstanding
- 48,847,340
- Total 13F shares
- 31,531,484
- Share change
- +31,528,209
- Total reported value
- $315,000,764
- Price per share
- $9.99
- Number of holders
- 70
- Value change
- +$314,968,047
- Number of buys
- 68
Quarterly Holders Quick Answers
What is CUSIP 008064206?
CUSIP 008064206 identifies JBIO - Jade Biosciences, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q3 2025
Recent filing periods for CUSIP 008064206:
Top shareholders of JBIO - Jade Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sofinnova Venture Partners X, L.P. |
3/4/5
13D/G
|
10%+ Owner · Sofinnova Venture Partners X, L.P. ("SVP X") |
0.3%
from 13D/G
|
3,758,686
|
$73,294,377 | — | 02 Jul 2021 | |
| David S. Grayzel |
3/4/5
|
Director |
—
mixed-class rows
|
1,811,732
mixed-class rows
|
$50,853,006 | — | 05 Jun 2024 | |
| Atlas Venture Fund XII, L.P. |
3/4/5
13D/G
|
10%+ Owner · Atlas Venture Associates XII, L.P. |
0.2%
from 13D/G
|
2,327,909
|
$45,394,226 | — | 15 Jul 2022 | |
| FMR LLC |
13D/G
13F
|
Company |
15%
|
4,735,951
|
$40,965,976 | $0 | 30 May 2025 | |
| Cormorant Asset Management, LP |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
2,030,691
|
$39,598,475 | — | 02 Jul 2021 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · 10%+ Owner |
—
mixed-class rows
|
9,192,092
|
$23,072,151 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
—
class O/S missing
|
3,758,686
|
$9,434,302 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
—
class O/S missing
|
2,240,809
|
$5,624,431 | — | 31 Mar 2025 | |
| Timothy P. Noyes |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director |
—
class O/S missing
|
343,381
|
$5,621,147 | — | 16 May 2024 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
1,799,232
|
$4,516,072 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
—
class O/S missing
|
1,461,234
|
$3,667,697 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
—
class O/S missing
|
1,440,499
|
$3,615,652 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
—
class O/S missing
|
1,421,568
|
$3,568,136 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
—
class O/S missing
|
1,400,000
|
$3,514,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
1,066,996
|
$2,678,160 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
—
class O/S missing
|
959,294
|
$2,407,829 | — | 31 Mar 2025 | |
| Blackstone Inc. |
13F
|
Company |
—
class O/S missing
|
955,125
|
$2,397,364 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
800,000
|
$2,008,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
699,438
|
$1,755,590 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
—
class O/S missing
|
600,000
|
$1,506,000 | — | 31 Mar 2025 | |
| Hunter Gillies |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
89,112
mixed-class rows
|
$1,504,308 | — | 13 Jun 2024 | |
| Cable Car Capital, LP |
13F
|
Company |
—
class O/S missing
|
589,780
|
$1,480,348 | — | 31 Mar 2025 | |
| Marinus Verwijs |
3/4/5
|
CHIEF TECHNICAL OFFICER |
—
class O/S missing
|
68,800
|
$1,126,256 | — | 14 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
—
class O/S missing
|
368,540
|
$925,035 | — | 31 Mar 2025 | |
| Timothy Pigot |
3/4/5
|
CHIEF COMMERCIAL OFFICER |
—
mixed-class rows
|
67,877
mixed-class rows
|
$923,420 | — | 22 Jan 2024 | |
| DELTEC ASSET MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
361,804
|
$908,128 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
—
class O/S missing
|
352,669
|
$885,199 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
295,080
|
$740,786 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
—
class O/S missing
|
291,800
|
$732,418 | — | 31 Mar 2025 | |
| TCG Crossover GP I, LLC |
13D/G
|
— |
0.2%
|
64,023
|
$649,193 | $0 | 28 Apr 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
246,914
|
$619,754 | — | 31 Mar 2025 | |
| George A. Eldridge |
3/4/5
|
Officer Title: Chief Financial Officer and Treasurer |
—
mixed-class rows
|
33,785
mixed-class rows
|
$596,551 | — | 14 Jun 2024 | |
| Ralph Niven |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
43,341
mixed-class rows
|
$591,035 | — | 05 Feb 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
—
class O/S missing
|
204,791
|
$514,025 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
—
class O/S missing
|
109,217
|
$274,135 | — | 31 Mar 2025 | |
| Lawrence Otto Klein |
3/4/5
|
Director |
—
mixed-class rows
|
109,232
mixed-class rows
|
$229,331 | — | 29 Apr 2025 | |
| Allison Dorval |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| Donald J. Santel |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| Habib J. Dable |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| Iwicki Mark T. |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| Joshua Resnick |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| Maha Katabi |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
12,500
|
$204,625 | — | 05 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
—
class O/S missing
|
75,674
|
$189,942 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
—
class O/S missing
|
74,440
|
$186,845 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
—
class O/S missing
|
69,910
|
$175,474 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
69,754
|
$175,083 | — | 31 Mar 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
—
class O/S missing
|
59,097
|
$148,333 | — | 31 Mar 2025 | |
| Verition Fund Management LLC |
13F
|
Company |
—
class O/S missing
|
55,520
|
$139,355 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
—
class O/S missing
|
54,000
|
$135,540 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
—
class O/S missing
|
40,047
|
$100,518 | — | 31 Mar 2025 |
Institutional Holders of Jade Biosciences, Inc. - Common Stock (JBIO) as of Q2 2025
As of 30 Jun 2025,
Jade Biosciences, Inc. - Common Stock (JBIO) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,531,484 shares.
The largest 10 holders included
FMR LLC, Fairmount Funds Management LLC, VR ADVISER, LLC, Deep Track Capital, LP, VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Versant Venture Management, LLC, RTW INVESTMENTS, LP, and Driehaus Capital Management LLC.
This page lists
70
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
102
Q2 2025 holders
70
Holder diff
-32
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.